Drug Approval | May 31, 2021
Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The GMP certificate is valid for three years until April 2024.
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
Subscribe To Our Newsletter & Stay Updated
